Pancreatic Cancer Research

ResearcherHouston MethodistActive in the last 2 years

Helen E Heslop

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7049-7698; OpenAlex author ID A5021029688; NIH RePORTER profile ID 2413379. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
1
Labs led
1
Collaborators
8
Papers, trials and grants by year

2017: 1 paper, 1 grant · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Co-author DOI 10.1038/s41591-025-04043-5↗
  2. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2016.10.016↗

Grants 1

  1. ENHANCING T CELL THERAPY OF CANCER P01CA094237↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ann Marie Leen · 2 shared papers, 1 shared grant, 2017–2026 · strength 0.52
  2. Cliona M. Rooney · 2 shared papers, 1 shared grant, 2017–2026 · strength 0.52
  3. Brandon George Smaglo · 1 shared paper, 2026 · strength 0.22
  4. George Van Buren · 1 shared paper, 2026 · strength 0.22
  5. Benjamin Musher · 1 shared paper, 2026 · strength 0.22
  6. Somala Mohammed · 1 shared paper, 2017 · strength 0.07
  7. William E. Fisher · 1 shared paper, 2017 · strength 0.07
  8. Juan F. Vera · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.